Custom Search

Register
Sign In
Sign In Using Facebook

Thailand may Get Cancer Drug Free from Novartis

November 22, 2007 at 12:52 PM Drug News
  •   Print
  •   Share
  •   Comments
  •  Text 
Thailand could get a cancer medicine from Norvatis for free if it slows its drive for generic versions of patented drugs, the country's health minister said Wednesday.
Thailand may Get Cancer Drug Free from Novartis


Thailand is at the forefront of an international battle with pharmaceutical companies over so-called compulsory licenses, which temporarily suspend patent protections.

The government has already issued compulsory licenses to get copycat versions of a heart drug and two key AIDS medicines. In September, it announced that it would also seek generic versions of four cancer drugs.

During talks with Novartis over its cancer-fighting Imatinib, Health Minister Mongkol Na Songkhla said the company had offered to provide the drug for free if Thailand halts its drive to expand its generic drug programme.

If a deal were reached, the government could provide unlimited amounts of the drug through its universal health care scheme, he said.

Imatinib currently costs as much as 100,000 baht (2,950 dollars) per patient per month.

"Novartis proposed to us to give free Imatinib without condition and limit in amount and time. We are in the final process of discussion," Mongkol told a seminar on compulsory licensing (CL) in Bangkok.

He said talks with two other drugmakers on cheaper prices for cancer drugs were also making progress.

"If this is successful, there will be no need for the government to implement more CL" on other drugs, he added.

Thailand has so far imposed compulsory licenses for the blockbuster heart drug Plavix and the AIDS medicines Kaletra and Efavirenz.

It has already begun importing cheaper versions from India, a major source of generic drugs.

Mongkol refused to rule out the possibility that the country would seek generic versions of other drugs in extraordinary circumstances.

"I won't say that we will do it again or not. We will do more CL only (on an) exceptional basis," he told reporters.

He also said that the government was considering legal action against Abbott, which withdrew an advanced version of Kaletra from the Thai market after the compulsory license was issued.

Thailand has a law that bars pharmaceutical companies from limiting access to their drugs if the medicine is available in other countries.

"The commerce ministry has been under negotiations with Abbott and considering a chance for legal action against the company," he said.

Source-AFP
SRM/P

 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
Comment & Contribute
Be the first to comment!
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  

X
  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Oncology - Focus on Cancer Prevention
News Archive
Date :
Category :
Keyword :
Quiz on Cancer
Looking for information on cancer? Go through medindia's Cancer quiz.
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
Cancer
Complete Medindia Resources
News Categories:  
Vision Health Center

Drug Related News

» New Guidelines Recommend Metformin to Treat Type 2 Diabetes » Novel Prostate Cancer Drug Target Identified
» Aspirin Helps Prevent DVT » Amgen's Xgeva to be Probed by FDA Panel
» FDA Takes a Closer Look at Dietary Supplements » Certain Cancer Drugs Boost Fatal Side Effects
» Anti-cancer Drug Causes Bone Loss » Patients With Primary Biliary Cirrhosis can be Treated With Rituximab
Read More >>